依达拉奉对急性脑梗死患者血清炎症因子水平的影响

目的观察依达拉奉对急性脑梗死患者血清炎症因子白细胞介素-6（IL-6）、肿瘤坏死因子（TNF-α）和超敏C反应蛋白（hs—CRP）水平的影响。方法选择急性脑梗死患者120例，随机分为依达拉奉组60例和常规治疗组60例，选择门诊健康体检者60例作为正常对照组。所有脑梗死患者均于入院时、治疗后3d、7d、14d分别抽静脉血3mI检测血清中IL-6、TNF-α、hs-CRP含量各1次，门诊健康体检者仅测定1次血清IL-6、TNF-α、hs-CRP含量。结果脑梗死患者血清IL-6、TNF-α及hs-CRP浓度水平较健康体检组明显升高（P〈0．01）。依达拉奉组和常规治疗组治疗前血清IL-6、TNF-α及hs-CRP含量测定无明显差异（P〉0．05），治疗后依达拉奉组血清IL-6、TNF-α浓度治疗后3d、7d和14d逐步下降，较常规治疗组有显著差异（P〈0．01）。依达拉奉组治疗后7d和14d血清hs-CRP浓度含量测定明显降低（P〈0．05和P〈0．01）；常规治疗第14天血清hs-CRP浓度才明显降低（P〈0．05）；两组间治疗第7天和第14天有显著差异（P〈0．05）。依达拉奉对于中重度病情患者的血清IL-6、TNF-α、hs—CRP水平的影响比轻度病情患者影响更大。结论急性脑梗死患者血清IL-6、TNF-α和hs—CRP含量明显增加，依达拉奉能显著降低急性脑梗死患者血清炎症因子IL-6、TNF—α和hs—CRP的水平，且对病情重者影响更明显。

Objective To study the effects of edaravone on levels of inflammatory factors interleukin -6 （IL-6）, tumor necrosis factor -α（TNF-α） and high sensitive C-reactive protein （hs-CRP） in patients with acute cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into edaravone group （n = 60 ）and conventional therapy group （n = 60） , and 60 cases healthy were selected as the normal control group. Respectively 3 ml venous blood of all patients with cerebral infarction were collected at the time of admission, the 3 d, 7 d and 14d after treatment. Then the serum IL-6, TNF-α and hs-CRP levels of all patients were detected. Results The IL-6, TNF-α and hs-CRP levels in cerebral infarction patients were significantly higher than those in healthy subjects （ P 〈 0. 01 ）. There were no significant difference （ P 〉 0.05 ） in levels of IL-6, TNF-α and hs-CRP between edaravone group and conventional treatment group before treatment. With the time prolonged, the levels of IL-6, TNF-α in edaravone group were gradually decreased at the 3 d ,7 d and 14 d after treatment, and were significantly different compared with conventional treatment group （P 〈 0. 01 ）. The hs-CRP levels in edaravone group decreased significantly at the 7 d, 14 d after treatment （P 〈 0. 05 and P 〈 0. 01 ） ,where as those in conventional treatment group showed significantly decreased at the 14 d after treatment （P 〈 0. 05 ） compared with those of before treatment, and the hs-CRP levels in edaravone group were higher than those in conventional treatment group at the 7 d and 14 d （ P 〈 0. 05 ）. Edaravone had more apparent effects on the IL-6, TNF-α, hs-CRP levels in patients with moderate and severe damage than those in patients with mild damage. Conclusion The IL-6, TNF-α and hs-CRP levels in patients with acute cerebral infarction are significantly increased than those in normal group. Edaravone could significantly decrease the inflammatory factor IL-6, TNF-α and hs-CRP levels, and have more effects on patients with severe damage.